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Using octyl glucoside-solubilized cell extracts from human fibroblasts during growth phase to GdG, arrest state, we found that while the number 
of M, 120 kDa rasGTPase-activating protein (pl20GAP) molecules per cell decreases to half its original levels, the amount of neurofibromatosis 
type 1 gene product (NFl. neurofibromm) remains constant during the transition. The contribution of p120GAP to the total rasGTPase-activating 
(rasGA) activity in growing cells was found to be larger than that observed in arrested cells (84% vs 53%). On the other hand, NFl contributes 
less than 15% of the total rasGA activity in either extract. These results indicate that the qualitative changes occur in the contributors to rasGA 
activity durmg transition. They also suggest that a unique rasGA activity exists m the arrested cells, which was obtained separatedly from both 
pl20GAP and NFl by heparin-Sepharose column chromatography. 
Ras; GTPase-activating protein; Neurofibromatosis type 1 gene product: Cell growth arrest; Human fibroblast 
1. INTRODUCTION 
In the last decade, studies on signal transduction sys- 
tems have revealed the importance of regulatory reac- 
tions between receptors and effecters , or so-called cou- 
pling reactions, including tyrosine phosphorylation [ 11. 
The GTPase-activating proteins of ras oncogene prod- 
uct p21 (rasGAPs) have been considered to be crucial 
elements in such systems for tyrosine kinase-mediated 
pathways. p21’““, which binds GDP/GTP and has an 
intrinsic GTPase activity, is localized on the inner sur- 
face of the plasma membrane [2,3] and the amount of 
its GTP binding form increases upon stimulation of 
cells with growth factors, such as epidermal growth 
factor and remains at high levels in v-src-transformed 
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cells [4]. At present, two different kinds of rasGAPs are 
known, Mr 120 kDa rasGAP (pl2OGAP) [5] and neu- 
rofibromatosis type 1 gene product (NFl) [6,7]. Al- 
though these two rasGAPs play important roles in the 
negative regulation of cell growth [S-l 11, several lines 
of evidence indicate that they play different roles in the 
regulation of ~21’““. For example, only pl20GAP has 
src homology 2 (SH2) regions through which it can 
associate with tyrosine phosphorylated receptors, such 
as those for epidermal growth factor upon the ligand 
stimulation [12]. In this way, pl20GAP forms oligom- 
eric complexes with M, 62 kDa [ 131 and M, 190 kDa [14] 
cellular proteins resulting in a reduction in rasGA activ- 
ity [15]. 
It is important to clarify the functional difference 
between pl20GAP and NFl. On this point, it is note- 
worthy that rasGA activity is reported to increase in 
proportion to the cell density of BALB/c3T3 and 
NIH3T3 cells [16,17], a finding that might be related to 
contact inhibition of cell growth. These observations 
prompted us to investigate quantitative and qualitative 
changes in rasGA activity at the molecular level, fo- 
cussing especially on the contribution of pl20GAP and 
NFl during the transition from growth phase to ar- 
rested state. In this report, we describe differential 
changes in pl20GAP and NFl during this process. We 
also suggest that a unique rasGA activity, which may 
be due to a new rasGAP(s) other than those attributable 
to pl20GAP and NFl, increases in the arrested state. 
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2. MATERIALS AND METHODS 2.7. Estimatton of the contrtbutton of NFI to the total rusGA actiwty, 
by mhibitton with antt-NFl-GRD anttserum 
2.1. Cell culture 
Human fibroblasts TIC-3 [18] were obtained from the Japanese 
Cancer Research Resources Bank and cultured in minimum essential 
medium supplemented with 10% fetal calf serum (HyClone) under 5% 
CO? 
2.2. Preparation of cell extracts and determmatton of cell number 
The rasGA activities of recombinant NFl-GRD (0.48 ng). rat brain 
P-100 (32 4 pug), the rat brain NFl fraction separated by Superose 6 
gel filtration (24.0 pg), and pl20GAP-depleted cell extracts prepared 
as described above (78.2 ,ug of 2-day cultures and 64.7 ,ug of 9-day 
cultures, respectively) were assayed in the presence of various amounts 
of anti-NFl-GRD antiserum supplemented with normal serum so that 
the total amount of serum in the reaction mixtures remained constant. 
The cells were solubihzed by somcation m extraction buffer (10 mM 
HEPES-NaOH, pH 7.4, 15 mM KCl. 1 mM MgCl,. 1 mM dithiothre- 
itol (DTT), 100 ,uM Na,VO,. 1 ,uM Okadaic acid, 1 mM phenylmeth- 
ylsulfonyl fluoride, 10 &ml antipain, 10 &ml pepstatin A. 10 @ml 
leupeptm, and 10 ,@ml E-64) containing 1% (w/v) octyl glucoside to 
a final protein concentration of about 10 mg/ml (60-100 pi/dish). An 
aliquot was taken for the measurement of cell number by evaluation 
of P, derived from phospholipid [19]. The homogenates were then 
centrifuged at 10.000 x g for 15 min and glycerol was added to the 
resultant supernatants at a final concentration of 10%. For heparin- 
column chromatography, the cells were prepared by the method as 
described above without octyl glucoside (S-10 fraction). The protein 
concentrations were measured using a protein assay kit (Bio-Rad or 
Pierce). 
2.8. Preparation of rat brain S-100 and P-100 
Wistar rat brains were homogenized with a Polytron homogenizer 
in homogenizing buffer (10 mM HEPES-NaOH (pH 7.4), 15 mM KCI, 
1 mM DTT, 1 mM MgCI,. 1 mM phenylmethylsulfonyl fluoride, 5 
,&ml of following protease inhibitors: leupeptm. antipain, E-64 and 
pestatin A). S-100 and P-100 were obtained by the conventional meth- 
ods. P-100 fractions were prepared by resolving the pellets m homog- 
emzing buffer containing 1% (w/v) octyl glucoside. Glycerol was 
added to both S-100 and P-100 fractions at a final concentration of 
10%. 
2.3. Determinatron ofrasGA activtty 
c-Ha-ras protein was obtained as described previously [20]. GTP 
hydrolytic activity was determined m duplicate or triplicate by the 
cellulose membrane binding assay essentially as described previously 
1211. 
2.4. Measurement of the amounts of pl20GAP and NFI 
2.9. HeparrnSepharose column chromatography 
Rat brain S-100 (27 mg protein in 0.8 ml) or S-10 fractions of cells 
prepared as described above (6.6 mg protein m I ml) were applied to 
HiTrap Heparin (Pharmacia, 1 ml) equilibrated with buffer A (10 mM 
HEPES-NaOH (pH 7.4) 1 mM EGTA, 1 mM MgCl,, 1 mM DTT, 
10% glycerol, and protease inhibitors used m the preparation of brain 
extracts). Elution was achieved with a 40-ml (for rat brain) or 20-m] 
(for cells) lmear NaCl gradient (O-1 0 M) m buffer A. Fractions (0.5 
ml for rat brain or 0.25 ml for cells) were collected the rasGA activity 
(5 ,uI ahquots) was determined as described above. NaCl concentration 
was determined by titration of Cl- with AgNO,. 
The cell extracts were resolved by SDS-PAGE (6% for analysis of 
both pl20GAP and NFl. or 7.5% for pl20GAP) and transferred to 
polyvmylidene difluoride membranes (Bio-Rad) in the presence of 
0.1% SDS In 6% SDS-PAGE, the filter was cut into two pieces at the 
boundary of M, 150 kDa and both were processed for immunoblot- 
ting, the upper for the detection of NFl and the lower for pl20GAP. 
The filter was blocked with 10% skimmed milk in 10 mM Tris-HCI 
(pH 7.6), 150 mM NaCl. 0.1% Tween 20 (TBST) for 2 h at room 
temperature, and then incubated with mono-specific anti-p120GAP 
peptide antibody (6,~uglml) or anti-NFl-GRD [22] antiserum (lOO-fold 
dilution) in TBST containing 0.1% skimmed milk for 2 h. The filters 
were exposed to [“51]Protem A (0.5 ,LYml. Amersham) in TBST 
containing 0.05% skimmed milk for 1 h. The amounts of pl2OGAP 
or NFl were assessed by measuring image density using a Fuji Image 
Analyzer (BAS2000). 
3. RESULTS 
3.1. Decrease in the amount of pl2OGAP but not NFl 
during the transition from grohcth phase to arrested 
state 
In order to obtain quiescent cells. human fibroblasts 
2.5. Prepuration of anttsera 
Antibody against pl20GAP peptide was prepared in rabbits by 
inJecting synthesized cysteinyl 16-mer peptide(975-990th of human 
pl2OGAP) [23] according to conventional methods. Anti-whole 
pl20GAP antiserum was produced m mice by mjectmg recombinant 
rat pl2OGAP expressed m E. coli after purification by a combination 
of DEAE-ion exchange and heparn-acrylic beads column chromatog- 
raphies (M.K. and S.1 , unpublished data). Rabbit anti-NFl-GRD 
antiserum was prepared as described previously [24]. 
(2.5 x lo6 cells per 100~mm dish) were cultured without 
medium change. Under the culture conditions, the cells 
stopped growing around day 6 (data not shown). These 
cells were homogenized in octyl glucoside-containing 
buffer and the amounts of pl20GAP and NFl were 
measured by immunoblotting methods. A comparison 
of the distributions between the soluble and insoluble 
fractions shows that all of the pl20GAP (at least 94%). 
as well as most of the NFl (at least 83%), could be well 
solubilized (Fig. la), implying that the vast majority of 
both pl20GAP and NFl in the cells is taken into ac- 
count for each experiment. 
2.6. Removal of pl2OGAP from cell extracts 
Cell extracts were prepared from 2-day and 9-day cultures and each 
extract (200 ~1, about l-2 mg) was treated with a pre-formed complex 
of Staphyrococcus aureus-goat anti-mouse IgG and either preimmune 
serum or anti-pl20GAP antiserum. After 60 min incubation at 4”C, 
the supernatants and pellets were separated by centrifugation at 
10,000 x g for 5 min. To evaluate immunoprecipitation efficiency, the 
amounts of p12OGAP in both the supernatants and pellets were as- 
sessed by immunoblotting with anti-p120GAP peptide antibody as 
described above. 
It is noteworthy that while the total rasGA activity 
decreases slightly during the transition from growth 
phase to arrested state (Fig. lb), the amounts of 
pl20GAP and NFl change differently ; the amount of 
pl20GAP decreases gradually to about 50% of that in 
the growing state, while NFl protein levels remain con- 
stant ( Fig. la, lanes 1 and 2 vs. 3 and 4, and Fig. lb). 
Although another protein with M, 78 kDa, which local- 
izes preferentially in the detergent-insoluble fraction 
(Fig. la, lanes 5-S), crossreacts specifically with the 
anti-p120GAP peptide antibody, it hardly crossreacts 
with antiserum against recombinant pl20GAP 
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Fig. 1. Differential changes m the amounts of pl20CAP and NFl during the transition from growmg phase to arrested state in human fibroblasts. 
Cells were cultured for 2.4, 6, or 9 days and solubilized. 40 or 8Opg of protein in the soluble fraction (lanes 14) and constant volumes of insoluble 
fraction from the pellets solubilized with SDS (lanes 5-8) were resolved by 6% SDS-PAGE. The amounts of insoluble fraction applied were 
equivalent to five-times the amounts of the corresponding soluble fraction compared at the level of the volume of the original cell homogenates 
(indicated as 5x). Only the data from 2-day and 9-day cell cultures are shown in panel a. (b) The amounts of pl20GAP (m), NFl (a) and rasGA 
activity (~1) per cell were assessed as described in section 2 and are expressed relative to those in the 2-day cultures (100%). Results are 
means f S.E.M. of at least four independent experiments (n = &l 1). 
3.2. Removal of pl2OGAP from cell extracts by im- 
munoprecipitation and the contribution of pI2OGAP 
to the total rasGA activity 
Next we evaluated the contribution of pl20GAP to 
the total rasGA activity by measuring the residual 
rasGA activity in the supernatants after immunoprecip- 
itating pl20GAP molecules from the cell extracts with 
anti-p12OGAP antibody. This antibody efficiently im- 
munoprecipitates more than 75% of the pl20GAP mol- 
ecules in each cell extract (Fig. 2a). As shown in Fig. 2b, 
whereas more than two-thirds of the total rasGA activ- 
ity was removed from growing cell extracts, less than 
half of the activity was removed from extracts of ar- 
rested cells. These activities correspond to 84% (+ 13%, 
n = 3) and 53% (? 9%, n = 3) of the total rasGA activ- 
ity, respectively, when corrected for immunoprecipita- 
tion efficiency. 
3.3. Contribution of NFI to the total rasGA activity in 
cell extracts 
In addition to the difficulty in evaluating exactly the 
immunoprecipitation efficiency by immunoblotting due 
to the large size of the NFI molecule, the antiserum 
against NFI-GRD did not efficiently immunoprecipi- 
tate NFI in cell extracts. Therefore, we estimated the 
contribution of NFl to the total rasGA activity by 
measuring the decrease in the rasGA activity of 
pl20GAP-depleted cell extracts in the presence of anti- 
NFI -GRD antiserum. This antiserum completely inhib- 
its the rasGA activity of recombinant NFI-GRD and 
NFI partially purified from rat brain S-100 by Superose 
6 (Fig. 3). In the case of rat brain P-100 fractions, a rich 
source of NFl[30], the rasGA activity is inhibited by up 
to 40%; thus the contribution of NFI to the total rasGA 
activity can be estimated as 40%. Under these condi- 
tions, a significant inhibition in the rasGA activity of 
cell extracts from either growing phase- or arrested state 
cells could not be detected (data not shown). Therefore, 
we used cell extracts from which the pl20GAP mole- 
cules had been mostly removed by immunoprecipita- 
tion, despite some pl2OGAP contamination. As shown 
in Fig. 3, about a quarter of the rasGA activity was 
inhibited in the presence of anti-NFI-GRD antiserum 
in both pl20GAP-depleted growing and arrested cell 
extracts. These inhibition values correspond to 5-15% 
of each total rasGA activity, although these values are 
almost within the range of experimental error. Taken 
together with the results on the contribution of 
pl20GAP, the rasGA activity of growing cell extracts 
consists entirely of pl20GAP and NFI. In contrast, 
arrested cells may contain a unique rasGA activity (des- 
ignated as X) attributable to a species other than 
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Fig. 2. Removal of pl20GAP from cell extracts by lmmunoprecipitation and the contribution of pl2OGAP to the total rasGA activity Cell extracts 
were prepared from 2-day and 9-day cultures and pl20GAP molecules were removed from each cell extract. The amounts of pl?OGAP in both 
the supernatants and lmmunoprecipitates were assessed as shown m panel a The rasGA activity ofeach supernatant after treatment with preimmune 
serum (‘I’) or anti-pl2OGAP antlserum (0) was measured usmg various amounts of cell extracts as shown m panel b. 
pl20GAP and NFl, because the sum contribution of 
NFl and pl20GAP to the total rasGA activity does not 
exceed at most 80%. 
3.4. Separation of X(s). which also exists in rut brain 
S-100 and S-10 fractions of TIG-3 cells in the ar- 
rested state, bl’ column chromatograph~~ 
We found that rat brain S-100 also contains a rasGA 
activity other than those attributable to pl20GAP and 
NFl which accounts for half the total rasGA activity 
([24], M.K. and S.I. unpublished data). Therefore we 
applied S-100 to a heparin-Sepharose column in order 
to separate this unique rasGA activity. As shown in Fig. 
4a+:, a significant rasGA activity (nearly 32% of the 
total rasGA activity) elutes between 0.5-0.73 M NaCl 
with no detectable amounts of either pl20GAP or NFl, 
which elute at 0.4 M NaCl. Essentially the same profile 
of rasGA activity was observed when S-10 fractions of 
cells in the arrested state were applied to the same col- 
umn (Fig. 4d-f). These data strongly suggests the exis- 
tence of a new rasGAP molecule(s) other than 
pl20GAP and NFl. 
4. DISCUSSION 
In this paper we have described changes in the com- 
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Fig 3. Estimation of the contribution of NFl to the total rasGA 
activity by inhibitlon with antI-NFl-GRD antiserum. The rasGA ac- 
tivlties from different sources were measured in the presence of various 
amounts of anti-NFl-GRD antiserum as described m section 2. The 
activities are expressed relative to the activity found in the presence 
of preimmune serum (100%) Instead of antl-NFl-GRD antlserum. 
Recombmant NFl-GRD (A). rat bram NFl fraction without 
pl2OGAP (0). rat bram P-100 (.:) and plZOGAP-depleted cell extracts 
prepared from ‘-day cultures (11) or 9-day cultures (0). 
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Fig. 4. Detection of a unique rasGA activity other than those of pl2OGAP or NFl tn the fractions from heparinsepharose column chromatography. 
Rat brain S-100 or S-10 fractions from arrest state cells were separated and both the rasGA activity and the amounts of pl20GAP and NFl were 
determmed as described in section 2. The left part of the figure (a-c) shows the data for rat bram and the right (d-f) for TIG-3 cells: Cl- 
concentrations m panels a and d; rasGA activity and protein concentrations m panels b and e; and the amounts of pl20GAP and of NFl m panels 
c and f. 
position of the rasGA activity during the transition 
from growth phase to arrested state under conditions 
where the total activity does not change very much; the 
amount of pl20GAP decreases, while NFl remains 
constant. Including the present data, several lines of 
evidence indicate that pl20GAP and NFl regulate 
~21 To’ differently despite their common rasGA activity. 
In an in vitro study, the biochemical characteristics of 
pl20GAP and NF 1, including their enzymatic sensitivi- 
ties to lipids [25], salts [26], and detergents [27], have 
been shown to differ. although the truncated NFl- 
GRD, rather than full-length NFl, was used for com- 
parison. We found that the rasGA activity of NFl- 
GRD is more sensitive to octyl glucoside than that of 
pl20GAP, and that the final concentration of octyl glu- 
coside in the reaction mixtures should be below 0.1%. 
This situation makes it difficult to estimate the small 
contribution of NFl to the total rasGA activity even 
after removal of the major contributor, pl20GAP. In 
vivo, the levels of p21”“-GTP in tumor cell lines derived 
from malignant Schwanomas have been reported to be 
high, probably due to a decrease in NFl levels, while 
pl20GAP levels are normal [lo]. While pl20GAP also 
has potent activity as an effector of ~21’“” [28-301, such 
potent effector activity has not been recognized in the 
function of IRA, a homolog of NFlin Succharonzyces 
cerevisiae [3 11. 
We also suggest the existence of a new rasGAP(s) in 
both rat brain S-100 and the extracts of TIG-3 cells in 
the arrested state by demonstrating rasGA activity in 
another heparin-Sepharose column chromatography 
fraction (eluted at 0.7 M NaCl) separate from the frac- 
tion containing both pl20GAP and NFl (eluted at 0.4 
M NaCl). In addition to these data, the possibility that 
X(s) is an isomer of NFl (NFl type II) [32] or a nucle- 
otide exchange factor [33] appears to be excluded (M.K. 
and S.I., data not shown). 
It has been shown that the machinery of growth 
factor receptor in quiescent cells is negatively regulated 
in a similar way by increases in phosphotyrosine 
phosphatase activity [34]. Therefore it is reasonable to 
speculate that NFl and an unidentified rasGAP(s) con- 
tribute to the total rasGA activity to shut off tyrosine 
kinase-p2 l’“‘- mediated pathway and to keep the cells in 
the G,/G, state. 
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